Advertisement

Chinese firm applies for corona vaccine trial in B'desh

Follow The Hawk on Google News+ Follow

Advertisement


Dhaka: A Chinese firm Synovac Biotech has applied for the third phase clinical trials of vaccine against COVID-19 in Bangladesh, secretary of Health and Family Welfare Ministry Abdul Mannan said.

Bangladesh will get the benefit of getting the vaccine, he added.

Advertisement

It might take at least six months for the Chinese company to administer the vaccine to the general population of Bangladesh, officials said. The vaccine will be first administered to health workers aged 18-59.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Sinovac Biotech Ltd, a biopharmaceutical company, had stated on June 1, the company is 99 per cent sure that its COVID-19 vaccine, called CoronaVac, will work.

Sinovac has already received approval from the Chinese government authorities to conduct both Phase I and Phase II human clinical trials in China. The company has made significant progress in the development of CoronaVac.

Advertisement

The Phase I clinical trial, which evaluated the safety, tolerance, and preliminary immunogenicity of the COVID-19 vaccine, commenced in April.

Also read'Fatty liver-free campaign' in Ranchi from Nov 23, MoS Sanjay Seth to take lead

The company recently published pre-clinical results regarding CoronaVac, noting that the vaccine candidate was safe and provided protection to rhesus monkeys through an animal challenge study.

After preliminary observation of the safety profile of CoronaVac in the Phase I study, Sinovac began conducting Phase II trial in May that involved more than 1,000 volunteers. The Phase II clinical trial evaluated the immunogenicity and safety of the vaccine in a larger population in order to define dosage, regimen, and immunization schedule.

Sinovac has secured $15 million in funding to accelerate its COVID-19 vaccine development and is constructing a commercial vaccine production plant that is expected to produce up to 100 million doses annually.

According to a report by Sky News, when Luo Baishan, a researcher at Sinovac, was asked by their reporter whether he thought the vaccine would be successful, he said, "Yes, yes. It must be successful, 99 per cent (sure)."

—IANS

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST